To explore the predictive value of IL-1, IL-6, and TNF-α in the efficacy on xerophthalmia, we divided the patients into 2 groups according to clinical efficacy: a good efficacy group (n = 68 [cured patients + patients with markedly effective treatment]) and a poor efficacy group (n = 38 [patients with effective treatment + patients with ineffective treatment]). This evidence concerns the gene IL6 and Keratoconjunctivitis sicca.